Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.

Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana

doi:10.1007/s00280-008-0858-8

Imatinib is the treatment of choice for FIP1L1-PDGFRalpha (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.

Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose / Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana. - In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. - ISSN 0344-5704. - 63(6)(2009), pp. 1161-1163. [10.1007/s00280-008-0858-8]

Scheda prodotto non validato

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Titolo:	Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
Autori:	BRECCIA M CILLONI D CANNELLA L STEFANIZZI, CATERINA TAFURI, Agostino FAMA A SANTOPIETRO M SAGLIO G ALIMENA, Giuliana mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2009
Rivista:	CANCER CHEMOTHERAPY AND PHARMACOLOGY
Citazione:	Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose / Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana. - In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. - ISSN 0344-5704. - 63(6)(2009), pp. 1161-1163. [10.1007/s00280-008-0858-8]
Handle:	http://hdl.handle.net/11573/32241
Appartiene alla tipologia:	01a Articolo in rivista

File allegati a questo prodotto

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11573/32241

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Catalogo dei prodotti della ricerca

Scheda prodotto non validato

File allegati a questo prodotto